Product Description
Clarithromycin is used to treat certain bacterial infections, such as pneumonia (a lung infection), bronchitis (infection of the tubes leading to the lungs), and infections of the ears, sinuses, skin, and throat. It also is used to treat and prevent disseminated Mycobacterium avium complex (MAC) infection [a type of lung infection that often affects people with human immunodeficiency virus (HIV)]. It is used in combination with other medications to eliminate H. pylori, a bacterium that causes ulcers. Clarithromycin is in a class of medications called macrolide antibiotics. It works by stopping the growth of bacteria. (Sourced from: https://medlineplus.gov/druginfo/meds/a692005.html)
Mechanisms of Action: CYP3A Inhibitor,Protein Synthesis Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Approved
Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | China | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam
Approved Indications: Skin Ulcer | Otitis | Otitis Media | Pharyngitis | Duodenal Ulcer | Helicobacter Infections | Pneumonia, Bacterial | Bronchitis | Bronchitis, Chronic | Pneumonia | Maxillary Sinusitis | Sinusitis | Helicobacter Infections
Known Adverse Events: Abdominal Pain | Dysgeusia | Pain Unspecified | Diarrhea | Hypertension | Headache | Nasopharyngitis | Pharyngitis | Candidiasis | Candidiasis, Vulvovaginal
Company: Abbott Laboratories
Company Location: ABBOTT PARK IL 60064-3500
Company CEO: Robert B. Ford
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Benin, China, Japan, Korea, Singapore, Sweden, Taiwan, United States
Active Clinical Trial Count: 12
Highest Development Phases
Phase 3: Multiple Myeloma|Mycobacterium Infections|Mycobacterium avium-intracellulare Infection
Phase 2: Buruli Ulcer
Phase 1: Healthy Volunteers|Helicobacter Infections
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| BLMs4BU | P2 |
Recruiting |
Buruli Ulcer |
2026-05-31 |
|
| NCT04302324 | P2 |
Recruiting |
Multiple Myeloma |
2025-09-01 |
|
| MAC-LD | P3 |
Active, not recruiting |
Mycobacterium avium-intracellulare Infection|Mycobacterium Infections |
2025-07-17 |
|
| TNP-2198-10 | P1 |
Completed |
Helicobacter Infections |
2024-10-14 |